Evaluation of the Possibility of Correction of Doxorubicin-Induced Chronic Heart Failure in the Experiment with 3-Hydroxypyridine Acetylcysteinate and 3-Hydroxypyridine Succinate.

The possibility of correction of morphological changes in the myocardium and biochemical parameters of the blood with 3-hydroxypyridine acetylcysteinate in a dose of 25 mg/kg was studied in the model of doxorubicin-induced chronic heart failure in rats. It was found that 3-hydroxypyridine acetylcysteinate in a dose of 25 mg/kg produced less pronounced cardio-protective effect in experimental chronic heart failure than 3-hydroxypyridine succinate.

Experimental substantiation for the use of mexidol and 3-hydroxypyridine fumarate in chronic myocardial injury.

We studied the cardioprotective properties of mexidol and 3-hydroxypyridine fumarate in rat model of chronic myocardial injury. We found that 3-hydroxypyridine fumarate (25 mg/kg) produced more pronounced antioxidant and cardioprotective effects than mexidol (25 mg/kg).

Efficiency of structurally different antioxidants in combined myocardial damage in mice.

Cardioprotective effects of derivatives of 3-hydroxypyridine, benzimidazole, and a peptide substance were studied on the model of combined damage to the myocardium (catecholamines and physical exercises) in mice. The most pronounced antioxidant and cardioprotective effects were produced by 3-hydroxypyridine acetylcysteinate (50 mg/kg), benzimidazole derivative Be-2m (50 mg/kg), and peptide substance γ-glutamyl histamine (1 mg/kg).